Todd Chappell, MBA has experience running multiple drug development programs from discovery stage through to clinical trials. He also has experience working as an EIR at NIH and spent some time working in biotech venture capital, running a portfolio company that was acquired by Tetralogic Pharmaceuticals after bringing a lead compound to clinical trials.
|
Suresh Singh, PhD established the computational design group at Vitae Pharmaceuticals, which was acquired by Allergan, using SILCS technology. At Vitae he launched 7 drug development programs, 6 of which went to clinical trials. Most recently he served as Vice President of Computational Sciences at Hotspot Therapeutics, which recently raised a $45M series A financing.
|
W. Alex Meltzer, PhD is an expert in drug target identification and validation as a cancer and stem cell biologist. Prior to Rasio Therapeutics, Dr. Meltzer was a senior associate at a life science/deep tech start-up firm where he brought several life science products to market and a portfolio company to revenue. He also has experience as a biotech equity research analyst fellow at T. Rowe Price and a life science venture fellow at Osage University Partners
|
Sunhwan Jo, PhD has been head of Commercial Development at SilcsBio for four years where he was responsible for developing and maintaining the SILCS software platform. Dr. Jo specializes in chemical informatics, machine learning and drug discovery software development.
|
|
National Science Foundation |
© 2021 Rasio All Rights Reserved
